NCT03576937View on ClinicalTrials.gov

Achieving Value in Cancer Diagnostics: Blood Versus Tissue Molecular Profiling - a Prospective Canadian Study

CompletedOBSERVATIONAL

Enrollment

207

Participants

Timeline

Start Date

February 12, 2019

Primary Completion Date

October 30, 2020

Study Completion Date

April 30, 2023

Conditions

Non-small Cell Lung Cancer

Interventions

DIAGNOSTIC_TEST

GUARDANT360

GUARDANT360 is a validated cfDNA next-generation sequencing assay that identifies variants in 73 genes associated with several cancers.

Trial Locations (6)

Unknown

Tom Baker Cancer Centre, Calgary

BC Cancer Agency, Vancouver

Juravinski Cancer Centre, Hamilton

Ottawa Hospital Regional Cancer Centre, Ottawa

Princess Margaret Cancer Centre, Toronto

Jewish General Hospital, Montreal

All Listed Sponsors

lead

University Health Network, Toronto

OTHER

NCT03576937 - Achieving Value in Cancer Diagnostics: Blood Versus Tissue Molecular Profiling - a Prospective Canadian Study | Biotech Hunter | Biotech Hunter